scispace - formally typeset
D

Dongfang Wu

Researcher at Wuhan University

Publications -  8
Citations -  1841

Dongfang Wu is an academic researcher from Wuhan University. The author has contributed to research in topics: Internal medicine & Adverse effect. The author has an hindex of 3, co-authored 5 publications receiving 1456 citations.

Papers
More filters
Journal ArticleDOI

Attitudes and perceptions regarding antimicrobial use and resistance among medical students in Central China

TL;DR: Investigation of the attitudes and perceptions of senior medical students regarding antimicrobial use and resistance in Central China found that curriculum system in Chinese institutions should make an effort to optimize curriculum system to make the authors' future doctors better prepared for antimicrobial stewardship and prudent antimicrobial prescribing.
Journal ArticleDOI

Medication Patterns and Disease Progression Among 165 Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective, Observational Study

TL;DR: Medication patterns for COVID-19 were diverse but generally complied with the existing guideline, and a potential therapeutic time window of 72 hours might exist in non-severe patients, especially for antiviral drugs.
Journal ArticleDOI

An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients

TL;DR: Wu et al. as mentioned in this paper conducted a case series study of 165 consecutive hospitalized COVID-19 patients who were followed up until March 25, 2020, from a designated hospital in Wuhan, China, where patients were grouped by a baseline degree of severity: non-severe and severe.
Journal ArticleDOI

Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice.

TL;DR: High-level PON1 improved dysfunctional HDL and alleviated the development of atherosclerosis in Scarb1-/- mice, suggesting that Pon1 represents a promising target of HDL-based therapeutic strategy for HDL-related atherosclerotic cardiovascular disease.